ABBV vs AMGN — Key Metrics
| Metric | ABBV (ABBVIE INC) | AMGN (AMGEN INC) |
|---|---|---|
| Price | 286.01 | 443.89 |
| Market Cap | 505.56 Billion | 240.11 Billion |
| P/E (TTM) | 49.06 | 25.54 |
| P/B (Quarterly) | -109.235 | 18.033 |
| P/S (TTM) | 7.66 | 6.17 |
| Net Profit Margin (TTM) | 15.7 | 24.1 |
| Gross Margin (TTM) | 73.7 | 70.9 |
| ROE (TTM) | -201.0 | 85.6 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: ABBV.
Financial Metrics
| ABBV | Metrics | AMGN |
|---|---|---|
| $286.01 | Price | $443.89 |
| — | Market Capitalization | — |
| 49.06 | Price to Earnings Ratio | 25.54 |
| 7.66 | Price to Sales | 6.17 |
| 26.79 | Price to FCF Ratio | 25.06 |
| 10.39 | Price to Gross Profit | 8.7 |
| 50.75 | Price to R&D | 30.63 |
| 13.49 | Price to Current Assets | 6.99 |
ABBV vs AMGN at a glance
Abbvie INC (ABBV) and Amgen INC (AMGN) are both Drug Manufacturers - General companies in the Healthcare sector. ABBV is the larger, at $505.6 billion in market value against $240.1 billion for AMGN, about 2.1 times the size.
On trailing-twelve-month figures, ABBV trades at 49.1 times trailing earnings and AMGN at 25.5; net profit margins are 15.7% and 24.1%.
The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.